Jagsonpal Pharmaceuticals is acquiring an 85% stake in Aequitas Healthcare for ₹20.8 crore. This move shifts Jagsonpal from retail to omnichannel specialty healthcare, gaining access to hospital chains. The deal is funded by internal accruals and expected to close by July 2026.

Jagsonpal Pharmaceuticals Acquires 85% Stake in Aequitas Healthcare

Jagsonpal Pharmaceuticals will acquire an 85% equity stake in Aequitas Healthcare Private Limited for ₹20.8 crore. Aequitas Healthcare reported revenues of ₹53 crore in FY26.

Reader Takeaway: Strategic pivot to hospital segment achieved; execution risk in integration.

What just happened

Jagsonpal Pharmaceuticals has entered into a definitive agreement to acquire 85% of Aequitas Healthcare Private Limited. The deal is valued at ₹20.8 crore, with Jagsonpal funding the entire amount from its internal accruals. The current directors of Aequitas will retain the remaining 15% stake and continue their association with the business. The transaction is anticipated to be completed by July 15, 2026, pending standard closing conditions.

Why this matters

This acquisition signifies a major strategic shift for Jagsonpal Pharmaceuticals. The company is transitioning from its traditional focus on retail prescriptions to an 'Omnichannel Specialty healthcare' business model. This move is expected to grant Jagsonpal immediate access to institutional relationships with major hospital chains across India. The hospital segment is estimated to contribute about 10% of the total pharmaceutical industry sales.

The backstory

Aequitas Healthcare Private Limited, established in 2017, specializes in the sale and distribution of pharmaceutical products directly to hospitals. This acquisition allows Jagsonpal to tap into a growing segment of the healthcare market.

What changes now

The company's business model will evolve, integrating hospital-focused distribution with its existing retail prescription operations. This diversification aims to broaden Jagsonpal's revenue base and market reach.

Risks to watch

The primary concern for investors is the execution risk associated with integrating Aequitas's hospital-focused operations into Jagsonpal's existing organizational structure. Additionally, the deal's completion is contingent upon fulfilling customary closing conditions.

Peer comparison

While specific peer acquisitions were not detailed in the filing, the move aligns with a broader industry trend of pharmaceutical companies seeking to diversify beyond traditional retail models into more specialized and institutional sales channels.

Context metrics (time-bound)

• Aequitas Healthcare reported revenues of ₹53 crore in FY26.
• Jagsonpal Pharmaceuticals is acquiring 85% for ₹20.8 crore.
• The deal is expected to close by July 15, 2026.

What to track next

Investors will be closely watching the integration process between Jagsonpal and Aequitas, and how effectively the company leverages the new hospital distribution network to drive growth.